Machavariani Eteri, Bromberg Daniel J, Dumchev Kostyantyn, Esserman Denise, Earnshaw Valerie A, Pykalo Iryna, Filippovich Myroslava, Ivasiy Roman, Ahmad Bachar, Long Jiang, Haddad Marwan S, Madden Lynn M, Oliveros David, Dvoriak Sergii, Altice Frederick L
Yale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States.
Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States.
Int J Drug Policy. 2025 Feb;136:104682. doi: 10.1016/j.drugpo.2024.104682. Epub 2024 Dec 19.
People who inject drugs experience poor health and social outcomes which improve with opioid agonist therapies like methadone, yet provider stigma may influence healthcare utilization. In Ukraine, integrating methadone into primary care centers (PCCs) provides an opportunity to examine provider stigma and its impact on patient outcomes.
This sub-analysis included patients randomized to receive methadone in PCCs as part of an implementation trial in which the control group received methadone in specialty addiction clinics in Ukraine. Methadone integration in PCCs was supported through continuous tele-education for providers. Provider stigma towards people who inject drugs, methadone, and attitudes towards evidence-based practices were assessed at baseline, 12, and 24 months using standardized scales (range 1-10). Patient-level outcomes were measured bi-annually over 24 months using a quality health indicator (QHI) score, a percentage of guideline-concordant primary and specialty health services accessed. Linear mixed-effects models examined the changes in provider stigma and attitudes, and the association of these measures with patient outcomes.
The sample included 583 patients and the 112 providers in 24 clinics. Provider fear and stereotypes toward people who inject drugs improved significantly, by 0.6 (95 % CI 0.2-1.1) and 0.4 points (95 % CI 0.1-0.8), respectively, as did preference for methadone over abstinence-based treatment (0.7 points, 95 % CI 0.2-1.1). A 1-point improvement in provider prejudice correlated with a 7.0-point increase (95 % CI: 1.1-13.0) in patient primary care QHI scores at 12 months, while improved attitudes towards evidence-based practices were associated with an 8.3-point increase (95 % CI: 1.1-13.0). Preference for methadone maintenance over abstinence was associated with a 3.7-point increase (95 % CI: 0.6-6.7) in specialty care QHI scores at 12 months, and reduced stereotypes were associated with a 10.9-point increase (95 % CI: 1.2-20.7) at 24 months.
Integrating methadone into PCCs with the support of provider tele-education may reduce provider stigma, particularly fear and stereotypes, toward people who inject drugs and methadone maintenance. Reducing provider stigma has the potential to improve patient outcomes through increased access to preventive care and screenings.
注射毒品者健康状况不佳且社会结局较差,而美沙酮等阿片类激动剂疗法可改善这些情况,但医疗服务提供者的污名化态度可能会影响医疗服务的利用。在乌克兰,将美沙酮纳入初级保健中心(PCC)为研究医疗服务提供者的污名化态度及其对患者结局的影响提供了契机。
该子分析纳入了在PCC中随机接受美沙酮治疗的患者,这是一项实施试验的一部分,其中对照组在乌克兰的专科成瘾诊所接受美沙酮治疗。通过对医疗服务提供者进行持续的远程教育培训,支持在PCC中整合美沙酮。在基线、12个月和24个月时,使用标准化量表(范围为1 - 10)评估医疗服务提供者对注射毒品者、美沙酮的污名化态度以及对循证实践的态度。在24个月内,每半年使用质量健康指标(QHI)评分来衡量患者层面的结局,QHI评分是获得的符合指南的初级和专科医疗服务的百分比。线性混合效应模型研究了医疗服务提供者污名化态度和观念的变化,以及这些指标与患者结局之间的关联。
样本包括24家诊所的583名患者和112名医疗服务提供者。医疗服务提供者对注射毒品者的恐惧和刻板印象分别显著改善了0.6分(95%置信区间0.2 - 1.1)和0.4分(95%置信区间0.1 - 0.8),对美沙酮相对于基于禁欲的治疗的偏好也改善了0.7分(95%置信区间0.2 - 1.1)。医疗服务提供者偏见每改善1分,与12个月时患者初级保健QHI评分提高7.0分(95%置信区间:1.1 - 13.0)相关,而对循证实践态度的改善与提高8.3分(95%置信区间:1.1 - 13.0)相关。在12个月时,对美沙酮维持治疗相对于禁欲的偏好与专科护理QHI评分提高3.7分(95%置信区间:0.6 - 6.7)相关,在24个月时,刻板印象的减少与提高10.9分(95%置信区间:1.2 - 20.7)相关。
在医疗服务提供者远程教育培训的支持下,将美沙酮纳入PCC可能会减少医疗服务提供者对注射毒品者和美沙酮维持治疗的污名化态度,尤其是恐惧和刻板印象。减少医疗服务提供者的污名化态度有可能通过增加获得预防性护理和筛查的机会来改善患者结局。